Loading...
•
Dec 31, 2024
UroGen Q4 2024 Earnings Report
UroGen reported solid Q4 2024 results, with JELMYTO revenue growing 5% year-over-year, while the company advanced its oncology pipeline.
Key Takeaways
UroGen's Q4 2024 revenue reached $24.6 million, reflecting a 5% year-over-year increase driven by higher JELMYTO demand. The company posted a net loss of $37.5 million due to increased R&D and SG&A expenses. JELMYTO continues to see growth in new patient starts and prescribers, and UroGen remains focused on advancing its UGN-102 NDA submission and pipeline assets.
JELMYTO revenue grew 5% year-over-year to $24.6 million.
Net loss widened to $37.5 million from $26.0 million in Q4 2023.
Operating expenses increased due to higher R&D and SG&A investments.
Cash and cash equivalents stood at $241.7 million as of December 31, 2024.
UroGen
UroGen
UroGen Revenue by Segment
Revenue by Segment
JELMYTO Revenue
CapyFin.com Forward Guidance
UroGen expects continued revenue growth for JELMYTO in 2025 while focusing on the FDA review of UGN-102 and further advancing its pipeline.
Positive Outlook
- 2025 JELMYTO revenue expected to grow 8-12% to $94-$98 million.
- FDA PDUFA decision for UGN-102 expected by June 13, 2025.
- Cash reserves remain strong at $241.7 million.
- Continued growth in new prescribers and patient starts for JELMYTO.
- Advancing clinical trials for next-generation urothelial cancer treatments.
Challenges Ahead
- Net losses are expected to continue due to high R&D and SG&A costs.
- Increased financing expenses related to the RTW Investments obligation.
- Regulatory risks remain for the approval of UGN-102.
- Competitive pressures in the urothelial cancer treatment market.
- Uncertainty around macroeconomic factors affecting healthcare spending.